Loading...
Docoh

Reneo Pharmaceuticals (RPHM)

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

RPHM stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 22
29 Jun 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 121.09M 121.09M 121.09M 121.09M 121.09M 121.09M
Cash burn (monthly) 1.19M (no burn) 4.34M 3.8M 3M 3.2M
Cash used (since last report) 3.52M n/a 12.86M 11.27M 8.89M 9.49M
Cash remaining 117.57M n/a 108.23M 109.82M 112.2M 111.61M
Runway (months of cash) 98.9 n/a 24.9 28.9 37.4 34.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jun 22 Grey Michael G Stock Option Common Stock Grant Acquire A No No 2.09 17,500 36.58K 17,500
1 Jun 22 Paul W. Hoelscher Stock Option Common Stock Grant Acquire A No No 2.09 6,376 13.33K 6,376
1 Jun 22 Eric M Dube Stock Option Common Stock Grant Acquire A No No 2.09 17,500 36.58K 17,500
1 Jun 22 Muralidhar Bali Stock Option Common Stock Grant Acquire A No No 2.09 17,500 36.58K 17,500
1 Jun 22 Seltzer Stacey Denenberg Stock Option Common Stock Grant Acquire A No No 2.09 17,500 36.58K 17,500
13F holders Current Prev Q Change
Total holders 42 40 +5.0%
Opened positions 6 5 +20.0%
Closed positions 4 4
Increased positions 14 10 +40.0%
Reduced positions 5 11 -54.5%
13F shares Current Prev Q Change
Total value 224.78M 195.22M +15.1%
Total shares 26.29M 25.22M +4.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
NEA Management 4.79M $40.93M 0.0%
New Enterprise Associates 15 4.79M $58.53M 0.0%
Novo Holdings A/S 3.43M $29.33M 0.0%
RiverVest Venture Management 2.41M $20.6M 0.0%
Abingworth 2.07M $17.73M 0.0%
RiverVest Venture Fund III 2.06M $0 0.0%
Lundbeckfond Invest A/S 2.03M $17.37M NEW
Rock Springs Capital Management 1.14M $9.77M 0.0%
Aisling Capital Management 886.08K $7.58M 0.0%
Tybourne Capital Management 750K $6.41M 0.0%
Largest transactions Shares Bought/sold Change
Lundbeckfond Invest A/S 2.03M +2.03M NEW
Deerfield Management 0 -849.3K EXIT
FMR 36.7K -150.8K -80.4%
Ra Capital Management 0 -62.22K EXIT
Millennium Management 24.99K +24.99K NEW
BLK Blackrock 316.88K +22.59K +7.7%
BAC Bank Of America 32.96K +15.1K +84.5%
Qube Research & Technologies 13.48K +13.48K NEW
Vanguard 367.6K -10.16K -2.7%
Pinz Capital Management 28.36K +9.2K +48.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: accessible, accidental, adware, Africa, AHEAD, ATM, attendant, Australia, Austria, authentication, Belgium, borrowing, cap, carrier, categorized, CEO, CHMP, consecutive, credential, crystalline, deficiency, deploying, destruction, disorder, email, encryption, enzyme, Eurasian, expedient, exploitable, Extortion, facilitate, fashion, France, Germany, hindsight, home, incremental, indemnification, isozyme, Israel, Italy, Japan, Kent, kinase, Korea, Lebanon, lipoamide, metric, Mexico, MRSU, necessitate, network, offline, omitted, online, payout, peak, perpetrated, persistent, posture, processor, provisionally, PSU, purse, Pyruvate, reassessing, recipient, Rescue, ROU, SAYE, Sharesave, sophisticated, South, stuffing, successor, Taiwan, traditional, UCPA, unlawful, Utah, valuation, Zealand
Removed: account, accounted, adequacy, allocating, anesthesiologist, antidilution, appoint, assessed, attaining, bill, biometric, bound, capture, cataract, certainty, certified, charged, CJEU, CMC, commentary, comparing, compliant, comprising, conceived, consolidation, constitute, constituted, construction, contingency, contractually, CTR, database, dated, deceptive, declined, deductible, democratic, denied, dependence, dependency, deposit, deposited, destination, diagnose, Directive, disproportionately, divergence, documentation, dollar, doubt, draft, earned, EDPB, enacting, engineering, expensed, explicit, exploratory, expressly, feasibility, forgo, geographic, Globally, hacking, hardware, harming, Historically, hoping, incipient, indexed, initially, instrument, intangible, introduce, judged, lawful, leased, Leerink, liquidate, location, lodge, maker, mandatory, McArdle, media, mezzanine, minimization, minute, misrepresentative, mission, mitigate, monthly, noncompliant, notably, noted, nurse, partially, path, percent, performed, periodically, permitting, Pharma, phishing, portal, postpone, PPARa, premium, presentation, proportionate, pseudonymized, questionnaire, ranging, Realized, recovery, redemption, reference, regular, remeasurement, repealing, restructure, resumed, resumption, retention, revise, robust, safeguarding, segment, segregation, sensitivity, sharing, Shield, social, society, software, spam, supervisory, supplementary, symptom, tested, Topic, tranche, transactional, transmission, turnover, unavailability, undiscounted, unique, unit, unrealized, untested, validation, violated, virtually, website

Patents

Utility
Crystalline Ppar-delta Agonist
5 May 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Utility
Use of Ppar-delta Agonists In the Treatment of Mitochondrial Myopathy
21 Apr 22
Described herein is the use of PPARδ agonists in the treatment of mitochondrial myopathy.
Utility
Crystalline PPAR-delta agonist
8 Mar 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.
Utility
Use of a Ppar-delta Agonist In the Treatment of Fatty Acid Oxidation Disorders (Faod)
27 Jan 22
Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.
Utility
Crystalline Ppar-delta Agonist
27 Jan 22
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.